5
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Cytoreductive partial and radical nephrectomies provide equivalent oncologic outcomes in T1–2M1 renal cell carcinoma

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          To compare the effectiveness of cytoreductive partial nephrectomy (CPN) and cytoreductive radical nephrectomy (CRN) in the treatment of metastatic T1–T2 renal cell carcinoma (RCC).

          Methods

          We obtained the clinical and pathological data of patients with metastatic T1–T2 RCC who underwent CPN or CRN from the Surveillance, Epidemiology, and End Results (SEER) database ( https://seer.cancer.gov). Propensity score matching (PSM) was used to balance differences in characteristics between CPN and CRN cases. Kaplan-Meier survival analysis and univariate and multivariate Cox regression were used to assess the effect of partial nephrectomy (PN) versus radical nephrectomy (RN) on overall survival (OS) and cancer-specific survival (CSS).

          Results

          After screening, 866 eligible cases were obtained. During the 1–107 months of follow-up, 500 patients died, 453 (90.6%) of whom died of RCC. The tumor size in the CRN group was significantly greater than that in the CPN group. Kaplan-Meier survival analysis showed that there was no significant difference in OS and CSS between the CPN group and the CRN group before and after matching. Univariate and multivariate Cox regression analysis found that the risk factors for OS were older age at diagnosis [hazard ratio (HR) =1.02, P=0.008], non-clear cell renal cell carcinoma (ccRCC) pathological type (HR =1.69, P=0.002), number of metastases ≥2 (HR =2.13, P<0.001), and regional lymph node involvement (HR =2.22, P=0.004), while the risk factors for CSS were non-ccRCC pathological type (HR =1.51, P=0.021) and the number of metastases ≥2 (HR =2.24, P <0.001).

          Conclusions

          CPN can provide similar oncologic outcomes as can CRN in T1–2M1 cases, and tumor metastatic burden is a major risk factor for survival in these patients with metastatic renal cell carcinoma (mRCC).

          Related collections

          Most cited references25

          • Record: found
          • Abstract: found
          • Article: not found
          Is Open Access

          Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012.

          Cancer incidence and mortality estimates for 25 cancers are presented for the 40 countries in the four United Nations-defined areas of Europe and for the European Union (EU-27) for 2012. We used statistical models to estimate national incidence and mortality rates in 2012 from recently-published data, predicting incidence and mortality rates for the year 2012 from recent trends, wherever possible. The estimated rates in 2012 were applied to the corresponding population estimates to obtain the estimated numbers of new cancer cases and deaths in Europe in 2012. There were an estimated 3.45 million new cases of cancer (excluding non-melanoma skin cancer) and 1.75 million deaths from cancer in Europe in 2012. The most common cancer sites were cancers of the female breast (464,000 cases), followed by colorectal (447,000), prostate (417,000) and lung (410,000). These four cancers represent half of the overall burden of cancer in Europe. The most common causes of death from cancer were cancers of the lung (353,000 deaths), colorectal (215,000), breast (131,000) and stomach (107,000). In the European Union, the estimated numbers of new cases of cancer were approximately 1.4 million in males and 1.2 million in females, and around 707,000 men and 555,000 women died from cancer in the same year. These up-to-date estimates of the cancer burden in Europe alongside the description of the varying distribution of common cancers at both the regional and country level provide a basis for establishing priorities to cancer control actions in Europe. The important role of cancer registries in disease surveillance and in planning and evaluating national cancer plans is becoming increasingly recognised, but needs to be further advocated. The estimates and software tools for further analysis (EUCAN 2012) are available online as part of the European Cancer Observatory (ECO) (http://eco.iarc.fr). Copyright © 2013 Elsevier Ltd. All rights reserved.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found
            Is Open Access

            European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial

              The first interim analysis of the KEYNOTE-426 study showed superior efficacy of pembrolizumab plus axitinib over sunitinib monotherapy in treatment-naive, advanced renal cell carcinoma. The exploratory analysis with extended follow-up reported here aims to assess long-term efficacy and safety of pembrolizumab plus axitinib versus sunitinib monotherapy in patients with advanced renal cell carcinoma.
                Bookmark

                Author and article information

                Journal
                Transl Cancer Res
                Transl Cancer Res
                TCR
                Translational Cancer Research
                AME Publishing Company
                2218-676X
                2219-6803
                29 January 2023
                28 February 2023
                : 12
                : 2
                : 301-309
                Affiliations
                [1]deptDepartment of Urology, Tongji Hospital of Tongji Medical College , Huazhong University of Science and Technology (HUST) , Wuhan, China
                Author notes

                Contributions: (I) Conception and design: C Yang; (II) Administrative support: Z Hu; (III) Provision of study materials or patients: Z Hu, W Guan; (IV) Collection and assembly of data: J Tian, J Zhu; (V) Data analysis and interpretation: J Tian, X Zeng; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

                [#]

                These two authors contributed equally to this work.

                Correspondence to: Prof. Zhiquan Hu, MD; Chunguang Yang, MD. Department of Urology, Tongji Hospital, Huazhong University of Science and Technology (HUST), No. 1095, Jiefang Road, Wuhan 430030, China. Email: huzhiquan2000@ 123456163.com ; cgyang-hust@ 123456hotmail.com .
                Article
                tcr-12-02-301
                10.21037/tcr-22-1389
                10007872
                36915574
                af39384c-233b-4455-a01e-1bd40f6ae0e7
                2023 Translational Cancer Research. All rights reserved.

                Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0.

                History
                : 16 May 2022
                : 17 November 2022
                Funding
                Funded by: National Natural Science Foundation of China
                Award ID: No. 81702989
                Categories
                Original Article

                cytoreductive partial nephrectomy (cpn),radical nephrectomy (rn),outcomes,metastatic renal cell carcinoma (mrcc)

                Comments

                Comment on this article